Should Clinical Trials Be Terminated Early?
In many trials, interim analyses are often performed to decide whether the trial should be terminated early, for a variety of reasons. These reasons may include an imbalance in adverse events in one group versus the other(s), a situation in which, given the sample size, it would be impossible to dem...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Streiner, David L. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
3 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Repression of autophagy leads to acrosome biogenesis disruption caused by a sub-chronic oral administration of polystyrene nanoparticles - Zhou, Lixiao ELSEVIER, 2022, the international journal of drug therapy, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:41 ; year:2019 ; number:9 ; pages:1889-1891 ; extent:3 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.clinthera.2019.07.004 |
|---|
| Katalog-ID: |
ELV048025380 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV048025380 | ||
| 003 | DE-627 | ||
| 005 | 20230626021038.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191023s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clinthera.2019.07.004 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000759.pica |
| 035 | |a (DE-627)ELV048025380 | ||
| 035 | |a (ELSEVIER)S0149-2918(19)30347-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 690 |a 610 |a 600 |q VZ |
| 084 | |a 30.00 |2 bkl | ||
| 084 | |a 44.13 |2 bkl | ||
| 100 | 1 | |a Streiner, David L. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Should Clinical Trials Be Terminated Early? |
| 264 | 1 | |c 2019transfer abstract | |
| 300 | |a 3 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a In many trials, interim analyses are often performed to decide whether the trial should be terminated early, for a variety of reasons. These reasons may include an imbalance in adverse events in one group versus the other(s), a situation in which, given the sample size, it would be impossible to demonstrate superiority of one treatment (futility) or a significant difference between groups. This commentary argues that ending a trial prematurely for the latter reason is fraught with problems and often results in an overestimation of the effect that would have been obtained were the trial allowed to continue. It concludes that stopping a trial early for apparent superiority of a treatment should be avoided. | ||
| 520 | |a In many trials, interim analyses are often performed to decide whether the trial should be terminated early, for a variety of reasons. These reasons may include an imbalance in adverse events in one group versus the other(s), a situation in which, given the sample size, it would be impossible to demonstrate superiority of one treatment (futility) or a significant difference between groups. This commentary argues that ending a trial prematurely for the latter reason is fraught with problems and often results in an overestimation of the effect that would have been obtained were the trial allowed to continue. It concludes that stopping a trial early for apparent superiority of a treatment should be avoided. | ||
| 650 | 7 | |a research design |2 Elsevier | |
| 650 | 7 | |a ending trials |2 Elsevier | |
| 650 | 7 | |a randomized controlled trials |2 Elsevier | |
| 650 | 7 | |a statistics |2 Elsevier | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Zhou, Lixiao ELSEVIER |t Repression of autophagy leads to acrosome biogenesis disruption caused by a sub-chronic oral administration of polystyrene nanoparticles |d 2022 |d the international journal of drug therapy |g Amsterdam [u.a.] |w (DE-627)ELV007757921 |
| 773 | 1 | 8 | |g volume:41 |g year:2019 |g number:9 |g pages:1889-1891 |g extent:3 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.clinthera.2019.07.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 30.00 |j Naturwissenschaften allgemein: Allgemeines |q VZ |
| 936 | b | k | |a 44.13 |j Medizinische Ökologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 41 |j 2019 |e 9 |h 1889-1891 |g 3 | ||
| author_variant |
d l s dl dls |
|---|---|
| matchkey_str |
streinerdavidl:2019----:hudlnclraseem |
| hierarchy_sort_str |
2019transfer abstract |
| bklnumber |
30.00 44.13 |
| publishDate |
2019 |
| allfields |
10.1016/j.clinthera.2019.07.004 doi GBV00000000000759.pica (DE-627)ELV048025380 (ELSEVIER)S0149-2918(19)30347-9 DE-627 ger DE-627 rakwb eng 690 610 600 VZ 30.00 bkl 44.13 bkl Streiner, David L. verfasserin aut Should Clinical Trials Be Terminated Early? 2019transfer abstract 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In many trials, interim analyses are often performed to decide whether the trial should be terminated early, for a variety of reasons. These reasons may include an imbalance in adverse events in one group versus the other(s), a situation in which, given the sample size, it would be impossible to demonstrate superiority of one treatment (futility) or a significant difference between groups. This commentary argues that ending a trial prematurely for the latter reason is fraught with problems and often results in an overestimation of the effect that would have been obtained were the trial allowed to continue. It concludes that stopping a trial early for apparent superiority of a treatment should be avoided. In many trials, interim analyses are often performed to decide whether the trial should be terminated early, for a variety of reasons. These reasons may include an imbalance in adverse events in one group versus the other(s), a situation in which, given the sample size, it would be impossible to demonstrate superiority of one treatment (futility) or a significant difference between groups. This commentary argues that ending a trial prematurely for the latter reason is fraught with problems and often results in an overestimation of the effect that would have been obtained were the trial allowed to continue. It concludes that stopping a trial early for apparent superiority of a treatment should be avoided. research design Elsevier ending trials Elsevier randomized controlled trials Elsevier statistics Elsevier Enthalten in Elsevier Science Zhou, Lixiao ELSEVIER Repression of autophagy leads to acrosome biogenesis disruption caused by a sub-chronic oral administration of polystyrene nanoparticles 2022 the international journal of drug therapy Amsterdam [u.a.] (DE-627)ELV007757921 volume:41 year:2019 number:9 pages:1889-1891 extent:3 https://doi.org/10.1016/j.clinthera.2019.07.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 30.00 Naturwissenschaften allgemein: Allgemeines VZ 44.13 Medizinische Ökologie VZ AR 41 2019 9 1889-1891 3 |
| spelling |
10.1016/j.clinthera.2019.07.004 doi GBV00000000000759.pica (DE-627)ELV048025380 (ELSEVIER)S0149-2918(19)30347-9 DE-627 ger DE-627 rakwb eng 690 610 600 VZ 30.00 bkl 44.13 bkl Streiner, David L. verfasserin aut Should Clinical Trials Be Terminated Early? 2019transfer abstract 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In many trials, interim analyses are often performed to decide whether the trial should be terminated early, for a variety of reasons. These reasons may include an imbalance in adverse events in one group versus the other(s), a situation in which, given the sample size, it would be impossible to demonstrate superiority of one treatment (futility) or a significant difference between groups. This commentary argues that ending a trial prematurely for the latter reason is fraught with problems and often results in an overestimation of the effect that would have been obtained were the trial allowed to continue. It concludes that stopping a trial early for apparent superiority of a treatment should be avoided. In many trials, interim analyses are often performed to decide whether the trial should be terminated early, for a variety of reasons. These reasons may include an imbalance in adverse events in one group versus the other(s), a situation in which, given the sample size, it would be impossible to demonstrate superiority of one treatment (futility) or a significant difference between groups. This commentary argues that ending a trial prematurely for the latter reason is fraught with problems and often results in an overestimation of the effect that would have been obtained were the trial allowed to continue. It concludes that stopping a trial early for apparent superiority of a treatment should be avoided. research design Elsevier ending trials Elsevier randomized controlled trials Elsevier statistics Elsevier Enthalten in Elsevier Science Zhou, Lixiao ELSEVIER Repression of autophagy leads to acrosome biogenesis disruption caused by a sub-chronic oral administration of polystyrene nanoparticles 2022 the international journal of drug therapy Amsterdam [u.a.] (DE-627)ELV007757921 volume:41 year:2019 number:9 pages:1889-1891 extent:3 https://doi.org/10.1016/j.clinthera.2019.07.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 30.00 Naturwissenschaften allgemein: Allgemeines VZ 44.13 Medizinische Ökologie VZ AR 41 2019 9 1889-1891 3 |
| allfields_unstemmed |
10.1016/j.clinthera.2019.07.004 doi GBV00000000000759.pica (DE-627)ELV048025380 (ELSEVIER)S0149-2918(19)30347-9 DE-627 ger DE-627 rakwb eng 690 610 600 VZ 30.00 bkl 44.13 bkl Streiner, David L. verfasserin aut Should Clinical Trials Be Terminated Early? 2019transfer abstract 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In many trials, interim analyses are often performed to decide whether the trial should be terminated early, for a variety of reasons. These reasons may include an imbalance in adverse events in one group versus the other(s), a situation in which, given the sample size, it would be impossible to demonstrate superiority of one treatment (futility) or a significant difference between groups. This commentary argues that ending a trial prematurely for the latter reason is fraught with problems and often results in an overestimation of the effect that would have been obtained were the trial allowed to continue. It concludes that stopping a trial early for apparent superiority of a treatment should be avoided. In many trials, interim analyses are often performed to decide whether the trial should be terminated early, for a variety of reasons. These reasons may include an imbalance in adverse events in one group versus the other(s), a situation in which, given the sample size, it would be impossible to demonstrate superiority of one treatment (futility) or a significant difference between groups. This commentary argues that ending a trial prematurely for the latter reason is fraught with problems and often results in an overestimation of the effect that would have been obtained were the trial allowed to continue. It concludes that stopping a trial early for apparent superiority of a treatment should be avoided. research design Elsevier ending trials Elsevier randomized controlled trials Elsevier statistics Elsevier Enthalten in Elsevier Science Zhou, Lixiao ELSEVIER Repression of autophagy leads to acrosome biogenesis disruption caused by a sub-chronic oral administration of polystyrene nanoparticles 2022 the international journal of drug therapy Amsterdam [u.a.] (DE-627)ELV007757921 volume:41 year:2019 number:9 pages:1889-1891 extent:3 https://doi.org/10.1016/j.clinthera.2019.07.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 30.00 Naturwissenschaften allgemein: Allgemeines VZ 44.13 Medizinische Ökologie VZ AR 41 2019 9 1889-1891 3 |
| allfieldsGer |
10.1016/j.clinthera.2019.07.004 doi GBV00000000000759.pica (DE-627)ELV048025380 (ELSEVIER)S0149-2918(19)30347-9 DE-627 ger DE-627 rakwb eng 690 610 600 VZ 30.00 bkl 44.13 bkl Streiner, David L. verfasserin aut Should Clinical Trials Be Terminated Early? 2019transfer abstract 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In many trials, interim analyses are often performed to decide whether the trial should be terminated early, for a variety of reasons. These reasons may include an imbalance in adverse events in one group versus the other(s), a situation in which, given the sample size, it would be impossible to demonstrate superiority of one treatment (futility) or a significant difference between groups. This commentary argues that ending a trial prematurely for the latter reason is fraught with problems and often results in an overestimation of the effect that would have been obtained were the trial allowed to continue. It concludes that stopping a trial early for apparent superiority of a treatment should be avoided. In many trials, interim analyses are often performed to decide whether the trial should be terminated early, for a variety of reasons. These reasons may include an imbalance in adverse events in one group versus the other(s), a situation in which, given the sample size, it would be impossible to demonstrate superiority of one treatment (futility) or a significant difference between groups. This commentary argues that ending a trial prematurely for the latter reason is fraught with problems and often results in an overestimation of the effect that would have been obtained were the trial allowed to continue. It concludes that stopping a trial early for apparent superiority of a treatment should be avoided. research design Elsevier ending trials Elsevier randomized controlled trials Elsevier statistics Elsevier Enthalten in Elsevier Science Zhou, Lixiao ELSEVIER Repression of autophagy leads to acrosome biogenesis disruption caused by a sub-chronic oral administration of polystyrene nanoparticles 2022 the international journal of drug therapy Amsterdam [u.a.] (DE-627)ELV007757921 volume:41 year:2019 number:9 pages:1889-1891 extent:3 https://doi.org/10.1016/j.clinthera.2019.07.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 30.00 Naturwissenschaften allgemein: Allgemeines VZ 44.13 Medizinische Ökologie VZ AR 41 2019 9 1889-1891 3 |
| allfieldsSound |
10.1016/j.clinthera.2019.07.004 doi GBV00000000000759.pica (DE-627)ELV048025380 (ELSEVIER)S0149-2918(19)30347-9 DE-627 ger DE-627 rakwb eng 690 610 600 VZ 30.00 bkl 44.13 bkl Streiner, David L. verfasserin aut Should Clinical Trials Be Terminated Early? 2019transfer abstract 3 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In many trials, interim analyses are often performed to decide whether the trial should be terminated early, for a variety of reasons. These reasons may include an imbalance in adverse events in one group versus the other(s), a situation in which, given the sample size, it would be impossible to demonstrate superiority of one treatment (futility) or a significant difference between groups. This commentary argues that ending a trial prematurely for the latter reason is fraught with problems and often results in an overestimation of the effect that would have been obtained were the trial allowed to continue. It concludes that stopping a trial early for apparent superiority of a treatment should be avoided. In many trials, interim analyses are often performed to decide whether the trial should be terminated early, for a variety of reasons. These reasons may include an imbalance in adverse events in one group versus the other(s), a situation in which, given the sample size, it would be impossible to demonstrate superiority of one treatment (futility) or a significant difference between groups. This commentary argues that ending a trial prematurely for the latter reason is fraught with problems and often results in an overestimation of the effect that would have been obtained were the trial allowed to continue. It concludes that stopping a trial early for apparent superiority of a treatment should be avoided. research design Elsevier ending trials Elsevier randomized controlled trials Elsevier statistics Elsevier Enthalten in Elsevier Science Zhou, Lixiao ELSEVIER Repression of autophagy leads to acrosome biogenesis disruption caused by a sub-chronic oral administration of polystyrene nanoparticles 2022 the international journal of drug therapy Amsterdam [u.a.] (DE-627)ELV007757921 volume:41 year:2019 number:9 pages:1889-1891 extent:3 https://doi.org/10.1016/j.clinthera.2019.07.004 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 30.00 Naturwissenschaften allgemein: Allgemeines VZ 44.13 Medizinische Ökologie VZ AR 41 2019 9 1889-1891 3 |
| language |
English |
| source |
Enthalten in Repression of autophagy leads to acrosome biogenesis disruption caused by a sub-chronic oral administration of polystyrene nanoparticles Amsterdam [u.a.] volume:41 year:2019 number:9 pages:1889-1891 extent:3 |
| sourceStr |
Enthalten in Repression of autophagy leads to acrosome biogenesis disruption caused by a sub-chronic oral administration of polystyrene nanoparticles Amsterdam [u.a.] volume:41 year:2019 number:9 pages:1889-1891 extent:3 |
| format_phy_str_mv |
Article |
| bklname |
Naturwissenschaften allgemein: Allgemeines Medizinische Ökologie |
| institution |
findex.gbv.de |
| topic_facet |
research design ending trials randomized controlled trials statistics |
| dewey-raw |
690 |
| isfreeaccess_bool |
false |
| container_title |
Repression of autophagy leads to acrosome biogenesis disruption caused by a sub-chronic oral administration of polystyrene nanoparticles |
| authorswithroles_txt_mv |
Streiner, David L. @@aut@@ |
| publishDateDaySort_date |
2019-01-01T00:00:00Z |
| hierarchy_top_id |
ELV007757921 |
| dewey-sort |
3690 |
| id |
ELV048025380 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV048025380</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626021038.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191023s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.clinthera.2019.07.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000759.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV048025380</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0149-2918(19)30347-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">690</subfield><subfield code="a">610</subfield><subfield code="a">600</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">30.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Streiner, David L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Should Clinical Trials Be Terminated Early?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In many trials, interim analyses are often performed to decide whether the trial should be terminated early, for a variety of reasons. These reasons may include an imbalance in adverse events in one group versus the other(s), a situation in which, given the sample size, it would be impossible to demonstrate superiority of one treatment (futility) or a significant difference between groups. This commentary argues that ending a trial prematurely for the latter reason is fraught with problems and often results in an overestimation of the effect that would have been obtained were the trial allowed to continue. It concludes that stopping a trial early for apparent superiority of a treatment should be avoided.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In many trials, interim analyses are often performed to decide whether the trial should be terminated early, for a variety of reasons. These reasons may include an imbalance in adverse events in one group versus the other(s), a situation in which, given the sample size, it would be impossible to demonstrate superiority of one treatment (futility) or a significant difference between groups. This commentary argues that ending a trial prematurely for the latter reason is fraught with problems and often results in an overestimation of the effect that would have been obtained were the trial allowed to continue. It concludes that stopping a trial early for apparent superiority of a treatment should be avoided.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">research design</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ending trials</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">randomized controlled trials</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">statistics</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Zhou, Lixiao ELSEVIER</subfield><subfield code="t">Repression of autophagy leads to acrosome biogenesis disruption caused by a sub-chronic oral administration of polystyrene nanoparticles</subfield><subfield code="d">2022</subfield><subfield code="d">the international journal of drug therapy</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV007757921</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:41</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:9</subfield><subfield code="g">pages:1889-1891</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.clinthera.2019.07.004</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">30.00</subfield><subfield code="j">Naturwissenschaften allgemein: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.13</subfield><subfield code="j">Medizinische Ökologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">41</subfield><subfield code="j">2019</subfield><subfield code="e">9</subfield><subfield code="h">1889-1891</subfield><subfield code="g">3</subfield></datafield></record></collection>
|
| author |
Streiner, David L. |
| spellingShingle |
Streiner, David L. ddc 690 bkl 30.00 bkl 44.13 Elsevier research design Elsevier ending trials Elsevier randomized controlled trials Elsevier statistics Should Clinical Trials Be Terminated Early? |
| authorStr |
Streiner, David L. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV007757921 |
| format |
electronic Article |
| dewey-ones |
690 - Buildings 610 - Medicine & health 600 - Technology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
690 610 600 VZ 30.00 bkl 44.13 bkl Should Clinical Trials Be Terminated Early? research design Elsevier ending trials Elsevier randomized controlled trials Elsevier statistics Elsevier |
| topic |
ddc 690 bkl 30.00 bkl 44.13 Elsevier research design Elsevier ending trials Elsevier randomized controlled trials Elsevier statistics |
| topic_unstemmed |
ddc 690 bkl 30.00 bkl 44.13 Elsevier research design Elsevier ending trials Elsevier randomized controlled trials Elsevier statistics |
| topic_browse |
ddc 690 bkl 30.00 bkl 44.13 Elsevier research design Elsevier ending trials Elsevier randomized controlled trials Elsevier statistics |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| hierarchy_parent_title |
Repression of autophagy leads to acrosome biogenesis disruption caused by a sub-chronic oral administration of polystyrene nanoparticles |
| hierarchy_parent_id |
ELV007757921 |
| dewey-tens |
690 - Building & construction 610 - Medicine & health 600 - Technology |
| hierarchy_top_title |
Repression of autophagy leads to acrosome biogenesis disruption caused by a sub-chronic oral administration of polystyrene nanoparticles |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV007757921 |
| title |
Should Clinical Trials Be Terminated Early? |
| ctrlnum |
(DE-627)ELV048025380 (ELSEVIER)S0149-2918(19)30347-9 |
| title_full |
Should Clinical Trials Be Terminated Early? |
| author_sort |
Streiner, David L. |
| journal |
Repression of autophagy leads to acrosome biogenesis disruption caused by a sub-chronic oral administration of polystyrene nanoparticles |
| journalStr |
Repression of autophagy leads to acrosome biogenesis disruption caused by a sub-chronic oral administration of polystyrene nanoparticles |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
zzz |
| container_start_page |
1889 |
| author_browse |
Streiner, David L. |
| container_volume |
41 |
| physical |
3 |
| class |
690 610 600 VZ 30.00 bkl 44.13 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Streiner, David L. |
| doi_str_mv |
10.1016/j.clinthera.2019.07.004 |
| dewey-full |
690 610 600 |
| title_sort |
should clinical trials be terminated early? |
| title_auth |
Should Clinical Trials Be Terminated Early? |
| abstract |
In many trials, interim analyses are often performed to decide whether the trial should be terminated early, for a variety of reasons. These reasons may include an imbalance in adverse events in one group versus the other(s), a situation in which, given the sample size, it would be impossible to demonstrate superiority of one treatment (futility) or a significant difference between groups. This commentary argues that ending a trial prematurely for the latter reason is fraught with problems and often results in an overestimation of the effect that would have been obtained were the trial allowed to continue. It concludes that stopping a trial early for apparent superiority of a treatment should be avoided. |
| abstractGer |
In many trials, interim analyses are often performed to decide whether the trial should be terminated early, for a variety of reasons. These reasons may include an imbalance in adverse events in one group versus the other(s), a situation in which, given the sample size, it would be impossible to demonstrate superiority of one treatment (futility) or a significant difference between groups. This commentary argues that ending a trial prematurely for the latter reason is fraught with problems and often results in an overestimation of the effect that would have been obtained were the trial allowed to continue. It concludes that stopping a trial early for apparent superiority of a treatment should be avoided. |
| abstract_unstemmed |
In many trials, interim analyses are often performed to decide whether the trial should be terminated early, for a variety of reasons. These reasons may include an imbalance in adverse events in one group versus the other(s), a situation in which, given the sample size, it would be impossible to demonstrate superiority of one treatment (futility) or a significant difference between groups. This commentary argues that ending a trial prematurely for the latter reason is fraught with problems and often results in an overestimation of the effect that would have been obtained were the trial allowed to continue. It concludes that stopping a trial early for apparent superiority of a treatment should be avoided. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
9 |
| title_short |
Should Clinical Trials Be Terminated Early? |
| url |
https://doi.org/10.1016/j.clinthera.2019.07.004 |
| remote_bool |
true |
| ppnlink |
ELV007757921 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1016/j.clinthera.2019.07.004 |
| up_date |
2024-07-06T17:45:29.435Z |
| _version_ |
1803852635896283136 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV048025380</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626021038.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191023s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.clinthera.2019.07.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000759.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV048025380</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0149-2918(19)30347-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">690</subfield><subfield code="a">610</subfield><subfield code="a">600</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">30.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Streiner, David L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Should Clinical Trials Be Terminated Early?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In many trials, interim analyses are often performed to decide whether the trial should be terminated early, for a variety of reasons. These reasons may include an imbalance in adverse events in one group versus the other(s), a situation in which, given the sample size, it would be impossible to demonstrate superiority of one treatment (futility) or a significant difference between groups. This commentary argues that ending a trial prematurely for the latter reason is fraught with problems and often results in an overestimation of the effect that would have been obtained were the trial allowed to continue. It concludes that stopping a trial early for apparent superiority of a treatment should be avoided.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In many trials, interim analyses are often performed to decide whether the trial should be terminated early, for a variety of reasons. These reasons may include an imbalance in adverse events in one group versus the other(s), a situation in which, given the sample size, it would be impossible to demonstrate superiority of one treatment (futility) or a significant difference between groups. This commentary argues that ending a trial prematurely for the latter reason is fraught with problems and often results in an overestimation of the effect that would have been obtained were the trial allowed to continue. It concludes that stopping a trial early for apparent superiority of a treatment should be avoided.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">research design</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">ending trials</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">randomized controlled trials</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">statistics</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Zhou, Lixiao ELSEVIER</subfield><subfield code="t">Repression of autophagy leads to acrosome biogenesis disruption caused by a sub-chronic oral administration of polystyrene nanoparticles</subfield><subfield code="d">2022</subfield><subfield code="d">the international journal of drug therapy</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV007757921</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:41</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:9</subfield><subfield code="g">pages:1889-1891</subfield><subfield code="g">extent:3</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.clinthera.2019.07.004</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">30.00</subfield><subfield code="j">Naturwissenschaften allgemein: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.13</subfield><subfield code="j">Medizinische Ökologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">41</subfield><subfield code="j">2019</subfield><subfield code="e">9</subfield><subfield code="h">1889-1891</subfield><subfield code="g">3</subfield></datafield></record></collection>
|
| score |
7.3999624 |